Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month High - Here's Why

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $14.69 and last traded at $14.04, with a volume of 192730 shares traded. The stock had previously closed at $14.22.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NAGE shares. Roth Capital reaffirmed a "buy" rating and issued a $23.00 price target (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Wall Street Zen upgraded Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a research report on Sunday, June 22nd. Finally, Canaccord Genuity Group lifted their price target on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th.

Niagen Bioscience Trading Up 1.0%

The firm has a 50 day simple moving average of $11.30 and a two-hundred day simple moving average of $7.79. The company has a market capitalization of $1.00 billion, a PE ratio of 139.78 and a beta of 2.14.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.